Cost-effectiveness of live attenuated influenza vaccine versus inactivated influenza vaccine among children aged 24–59 months in the United States

详细信息	查看全文 | 推荐本文 |

• 作者：Bryan R. Luce ; Kristin L. Nichol ; Robert B. Belshe ; Kevin D. Frick ; Su Xia Li ; Audra Boscoe ; Matthew D. Rousculp ; Parthiv J. Mahadevia
• 关键词：Live attenuated influenza vaccine ; trivalent (LAIV) ; Trivalent inactivated influenza vaccine (TIV) ; Children ; Cost-effectiveness ; Influenza ; Influenza vaccine
• 刊名：Vaccine
• 出版年：2008
• 期刊代码：89_0264410x
• 类别：imm
• 出版时间：2 June 2008
• 卷：26
• 期：23
• 页码：2841-2848
• 文件大小：327 K

摘要

The US Advisory Committee on Immunization Practices (ACIP) recently expanded the influenza vaccine recommendation to include children 24–59 months of age. In a large head-to-head randomized controlled trial, live attenuated influenza vaccine, trivalent (LAIV) demonstrated a 54%relative reduction in culture-confirmed influenza illness compared with trivalent inactivated influenza vaccine (TIV) among children aged 24–59 months.